ReviewCardiovascular drugs and therapy2026
Ivabradine as a Cardio-Protective Agent Against Anthracycline-Induced Cardiotoxicity: A Narrative Review.
Review in Cardiovascular drugs and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeAnthracycline-induced cardiomyopathy (AIC) remains a major limitation in cancer therapy, significantly impacting patient survival and quality of life. Ivabradine, a selective heart rate-lowering agent, has recently attracted attention for its potential cardioprotective effects. This review aims to summarize and critically evaluate the mechanistic, preclinical, and clinical evidence supporting ivabradine's role in preventing or attenuating anthracycline-induced cardiotoxicity.
methodsA comprehensive literature review was conducted using databases including PubMed, Scopus, and Web of Science, focusing on studies investigating the effects of ivabradine on cardiac structure, function, and cellular mechanisms in the context of anthracycline therapy. Both experimental and clinical data were analyzed to identify patterns of cardioprotection and potential translational value.
resultsPreclinical studies demonstrate that ivabradine mitigates anthracycline-induced oxidative stress, inflammation, and mitochondrial dysfunction while preventing cardiomyocyte apoptosis and preserving myocardial performance. Clinical evidence suggests that ivabradine reduces cardiotoxicity, maintains left ventricular ejection fraction, and enhances myocardial efficiency without lowering blood pressure or diminishing chemotherapy efficacy.
conclusionIvabradine shows promising cardioprotective potential against anthracycline-induced cardiotoxicity through multiple cellular and functional mechanisms. However, it is not yet approved for this indication, and large-scale, randomized multicenter trials are required to confirm its efficacy and safety. Integrating ivabradine into precision cardio-oncology may represent a novel strategy to improve outcomes and quality of life in cancer patients receiving anthracycline-based therapy.
Indexed as
Identifiers
41128978What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.